In a large cohort study by Aro et al. (2025) including 1239 tumor samples, HER2 amplification was shown to occur predominantly within the p53-abnormal molecular subgroup, whereas low HER2 expression was distributed across various high-risk histological types [16]. The gene discussed is ERBB2; the disease is neoplasm.